Key player · Company profile
Boehringer Ingelheim GmbH
Named as a key player in 99 of our reports, across 33 regions and countries.
Named as a key player in 99 of our reports, across 33 regions and countries.
Australia 3
Brazil 3
Canada 3
China 3
Ecuador 3
Egypt 3
France 3
Germany 3
Hong Kong 3
India 3
Italy 3
Japan 3
Kenya 3
Malaysia 3
Mexico 3
New Zealand 3
Philippines 3
Russia 3
Saudi Arabia 3
Singapore 3
South Africa 3
Spain 3
Thailand 3
UAE 3
UK 3
US 3| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Asthma & COPD Drugs | Pharmaceuticals | $49.5 Bn | 4% |
| Anticoagulants | Pharmaceuticals | – | – |
| Biosimilar Monoclonal Antibodies | Pharmaceuticals | – | – |
Named as key players in the same markets as Boehringer Ingelheim GmbH (number of shared markets).
Novartis AG2 shared markets
Allergan (a subsidiary of AbbVie)1 shared market
Amgen Inc.1 shared market
Aspen Holdings1 shared market
AstraZeneca1 shared market
Bayer AG1 shared market
Biocon Limited1 shared market
Bristol-Myers Squibb Company1 shared market
Search all reports for Boehringer Ingelheim GmbH All companies